We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Instruments Automate PCR Diagnostic Applications

By LabMedica International staff writers
Posted on 27 Jan 2014
Two new diagnostic instruments, which recently have been certified for marketing in Europe (CE marked), will bring an unprecedented level of automation and efficiency to laboratories that process large and very large numbers of specimens on a daily basis.

The Roche Molecular Diagnostics (Pleasanton, CA, USA) Cobas 6800/8800 system has automated PCR technology for virology, blood screening, HPV (human papillomavirus and CT/NG (Chlamydia trachomatis and Neisseria gonorrhea) testing. More...
The system comes in two models—large (6800) and very-large (8800) throughput capacity—and was developed to deliver increased automation and throughput, with minimal user intervention and improved quality control.

The instruments are equipped with an onboard refrigerator to allow for significantly longer reagent storage capacity and less loading and unloading of reagents. The instrument design provides greater ergonomics in terms of the user-instrument interface, reducing the number of required user interactions. Once the instrument is loaded, the system can run continuously for eight or four hours for the Cobas 6800 and Cobas 8800 system, respectively. This translates into a throughput of 300 and 1000 results in eight hours, respectively. Once the instrument begins processing samples, the first 96 results can be reported within three-and-a-quarter hours. Thereafter, the Cobas 6800 and 8800 instruments provide up to 96 results every 90 or 30 minutes, respectively.

This level of efficiency was obtained by completely automating the processing of primary and secondary tubes all the way through to the patient sample result for any combination of three different tests at the same time. This parallel sample to result process is accomplished using a universal sample preparation, PCR profile, and reagent setup process.

During the first six months of the systems' CE launch, several assays will be available for virology labs (HIV, HCV, HBV, and CMV) and for blood screening labs (combined HIV/HCV/HBV, WNV, and combined Parvovirus B19/HAV). In the near future, the system will support additional assays including HPV, CT/NG, and a utility channel for user-defined applications.

Related Links:
Roche Molecular Diagnostics



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Immunofluorescence Analyzer
IFA System
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.